Structural and Functional Characteristics of the B-domain-deleted Recombinant Factor VIII Protein, r-VIII SQ

 

 Buy Article Permissions and Reprints

Summary

Recombinant factor VIII SQ (r-VIII SQ), ReFacto®, is a recombinant factor VIII product similar to the smallest active factor VIII protein found in plasma-derived factor VIII (p-VIII) concentrates. The protein comprises two polypeptide chains of 80 and 90 kDa and lacks the major part of the heavily glycosylated B-domain i.e. amino acids Gln744 to Ser1637. r-VIII SQ retains six potential glycosylation sites for N-linked oligosaccharides at asparagine residues 41, 239, 582, 1685, 1810 and 2118.

We describe a thorough comparison of the characteristics of r-VIII SQ with those of p-VIII. The primary and secondary structures of r-VIII SQ were in good agreement with that of B-domain-deleted p-VIII (p-VIII-LMW) as shown by SDS-PAGE, Western blotting with antifactor VIII antibodies, tryptic mapping, amino acid sequence analysis and circular dichroism spectroscopy. A few divergences also existed. Thus r-VIII SQ was shown to contain a small amount of the single chain primary translation product of 170 kDa and also the product specific sequence of 14 amino acids, the SQ-link, in the C-terminal end of the 90 kDa chain. It was shown that r-VIII SQ had a high specific activity of about 14,000 IU VIII:C/mg as determined by use of a chromogenic substrate assay. The r-VIII SQ protein was comparable to p-VIII forms with a retained B-domain, in terms of potency measured by a chromogenic substrate or a two-stage clotting assay, in interactions with thrombin, and with activated protein C (APC) in combination with Protein S. The ability of r-VIII SQ to participate as a cofactor in factor Xa generation in a mixture of factors IXa and X, phospholipid and calcium was in conformity with that of p-VIII. Furthermore r-VIII SQ had a good binding capacity for phospholipid vesicles and von Willebrand factor (vWF) as shown in gel filtration studies. The same kinetics in binding to von Willebrand factor was found for r-VIII SQ and p-VIII as determined by real-time biospecific interaction analysis (BIA) with use of the BIAcore® instrument. The apparent association rate constant was 4 × 10⁶ M⁻¹s⁻¹. Two dissociation rate constants were found, 1 × 10⁻²s⁻¹ and 4 × 10⁻⁴s⁻¹. The results extend the present knowledge that the factor VIII B-domain is dispensable for the factor VIII cofactor function in hemostasis.

• References

• 1 Vehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DP, Rotblat F, Opperman H, Keck R, Wood WI, Harkins RN, Tuddenham RM, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984; 312: 337-42.
  CrossrefPubMedGoogle Scholar
• 2 Toole JJ, Knopf JM, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-7.
  CrossrefPubMedGoogle Scholar
• 3 Andersson L-O, Forsman N, Huang K, Lundin A, Pavlu B, Sandberg H, Sewerin K, Smart J. Isolation and characterization of human factor VIII: Molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma. Proc Natl Acad Sci 1986; 83: 2979-83.
  CrossrefPubMedGoogle Scholar
• 4 Kaufman RL, Wasley LC, Dorner A J J. Synthesis, processing, and secretion of recombinant human factor VIII. Biol Chem 1988; 263: 6352-62.
  PubMedGoogle Scholar
• 5 Brinkhous KM, Sandberg H, Garris JB, Mattsson C, Palm M, Griggs T, Read MS. Purified human factor VIII procoagulant protein: Comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci 1985; 82: 8752-6.
  CrossrefPubMedGoogle Scholar
• 6 Lind P, Larsson K, Spira J, Sydow-Backman M, Almstedt A, Gray E, Sandberg H. Novel forms of B-domain-deleted recombinant factor VIII molecules, Construction and biochemical characterization. Eur J Biochem 1995; 232: 19-27.
  CrossrefPubMedGoogle Scholar
• 7 Bihoreau N, Paolantonacci P, Bardelle C, Fontaine-Aupart M-P, Krishnan S, Yon J, Romet-Lemonne J-P. Structural and functional characterization of factor VIII-delta II, a new recombinant factor VIII lacking most of the B-domain. Biochem J 1991; 277: 23-31.
  CrossrefPubMedGoogle Scholar
• 8 Pittman DD, Alderman E, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, immunological, and in vivo functional characterization of B-domain deleted factor VIII. Blood 1993; 81: 2925-35.
  PubMedGoogle Scholar
• 9 Toole JT, Pittman DB, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (c.95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci 1986; 83: 5939-42.
  CrossrefPubMedGoogle Scholar
• 10 Yang TW, Wu CSC, Martinez HM. Calculation of protein conformation from circular dichroism. In: Methods Enzymol. Hirs CHW, Timasheff SN. eds: Academic press INC; 1986. 130 208-26.
  Google Scholar
• 11 Denson KWE. The simplified two-stage assay for factor VIII. In: Human blood coagulation. Haemostasis and Thrombosis. 2nd ed.. Biggs R. ed. Blackwell Scientific Publication; 1976: 688-92.
  Google Scholar
• 12 Over J. Methodology of the one-stage assay of factor VIII (VIII:C). Scand J Haem Suppl 1984; 33: 13-24.
  PubMedGoogle Scholar
• 13 Margolis J. An improved procedure for accurate assay of factor VIII. Pathology 1979; 11: 149-59.
  CrossrefPubMedGoogle Scholar
• 14 Mertens K, Donath MJSH, Van Leen RW, Keyzer-Nellen MJM, Verbeet M Ph, Klaasse Bos JM, Leyte A, Van Mourik JA. Biological activity of recombinant factor VIII variants lacking the central B-domain and the heavy-chain sequence Lys⁷¹³-Arg⁷⁴⁰: discordant in vitro and in vivo activity. Brit J Haem 1993; 85: 133-42.
  CrossrefPubMedGoogle Scholar
• 15 Karlsson R, Michaelsson A, Mattsson C. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods 1991; 145: 229-40.
  CrossrefPubMedGoogle Scholar
• 16 Sandberg H, Brandt J, Alin P, Stromberg S, Gray E, Bartfai J, Castro V. Glycosylation pattern of a B-domain-deleted recombinant factor VIII molecule (r-VIII SQ). Thromb Haemost 1995; 73: 1214.
  PubMedGoogle Scholar
• 17 Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646-50.
  CrossrefPubMedGoogle Scholar
• 18 Rapaport SL, Schiffman S, Patch MJ, Ames SB. The importance of activation of antihemophilic globulin, and proaccelerin by traces of thrombin in the generation of intrinsic prothrombinase activity. Blood 1963; 21: 221-36.
  PubMedGoogle Scholar
• 19 Fay PJ, Anderson MT, Chavin SI, Marder VJ. The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim Biophys Acta 1986; 371: 268-78.
  PubMedGoogle Scholar
• 20 Bertina RM. The control of hemostasis: Protein C and Protein S. Biomedical Progress 1989; 4: 53-6.
  PubMedGoogle Scholar
• 21 Foster P, Fulcher C, Houghten R, Zimmerman T. An immunogenic region within residues Val¹⁶⁷⁰- Glu¹⁶⁸⁴ of Factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. J Biol Chem 1988; 263: 5230-4.
  PubMedGoogle Scholar
• 22 Leyte A, Verbeet M Ph, Brodniewicz-Proba T, Van Mourik JA, Mertens K. The interaction between human blood-coagulation factor VIII and von Willebrand factor. Biochem J 1989; 257: 679-83.
  CrossrefPubMedGoogle Scholar
• 23 Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269: 11601-5.
  PubMedGoogle Scholar
• 24 Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood 1990; 75: 1999-2004.
  PubMedGoogle Scholar
• 25 Nesheim M, Pittman DD, Giles AR, Fass DN, Wang JH, Slonosky D, Kaufman RJ. The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets. J Biol Chem 1991; 266: 17815-20.
  PubMedGoogle Scholar
• 26 Vlot A, Koppelman S, van den Berg M, Bouma B, Sixma J. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 1995; 85: 3150-7.
  PubMedGoogle Scholar
• 27 Rotblat F, O’Brien DP, O’Brien FJ, Goodall AH, Tuddenham GD. Purification of human factor VIII:C and its characterization by western blotting using monoclonal antibodies. Biochemistry 1985; 24: 4294-300.
  CrossrefPubMedGoogle Scholar
• 28 Hamer RJ, Koedam JA, Beeser-Visser NH, Sixma JJ. Human factor VIII: purification from commercial factor VIII concentrate, characterization, identification and radiolabeling. BBA 1986; 873: 356-66.
  PubMedGoogle Scholar
• 29 Koppelman SJ, Koedam JA, van Wijnen M, Stern DM, Nawroth PP, Sixma JJ, Bouma BN. Von Willebrand factor as a regulator of intrinsic factor X activation. J Lab Clin Med 1994; 123: 585-93.
  PubMedGoogle Scholar
• 30 Sandberg H, Andersson L-O, Hoglund S. Isolation and characterization of lipid-protein particles containing platelet factor 3 released from human platelets. Biochem J 1982; 203: 303-11.
  CrossrefPubMedGoogle Scholar
• 31 Brekkan E, Wrangel M, Sandberg H. The binding kinetics of B-domain-deleted recombinant factor VIII and plasma-derived factor VIII to phospholipid vesicles. Thromb Haem Suppl 1999; 235.
  PubMedGoogle Scholar
• 32 Berntorp E. Second generation, B-domain deleted recombinant factor VIII. Thromb Haemost 1997; 78: 256-60.
  Article in Thieme ConnectPubMedGoogle Scholar
• 33 Kjalke M, Heding A, Talbo G, Persson E, Thomsen J, Ezban M. Amino acid residues 721-729 are required for full factor VIII activity. Eur J Biochem 1995; 234: 773-9.
  CrossrefPubMedGoogle Scholar